EPHA2 and chondrosarcoma: This brings chondrosarcoma to the fore alongside osteosarcoma and Ewing’s sarcoma as a potential preclinical and clinical field of study for anti-EphA2 targeting and immunotherapeutic strategies, which are already ongoing, or with preliminary data in several cancer types (NCT02252211, NCT04180371, NCT02575261) [20,21,22,23].